510(k) device
Elecsys AMH
Roche Diagnostics · Anti-Müllerian Hormone Test System (PQO, Class II) · First FDA decision Jun 10, 2022, newest Jun 10, 2022Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Elecsys AMH"
MAUDE reports
12
Brand "Elecsys AMH", since 2015
PubMed studies
39
Mentioning "Elecsys AMH"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys AMH
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Elecsys AMH510(k)
K203757 · Decided Jun 10, 2022 · 534 days after receipt
Device type: Anti-Müllerian Hormone Test System (PQO) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys AMH", any status and sponsor, newest update first.
No registered device study names "Elecsys AMH".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys AMH", and for the whole product code for context.
This brand
12 reports: 12 malfunction, 0 injury, 0 death
Whole product code PQO
14 reports: 14 malfunction, 0 injury, 0 death
Newest reports for this brand
- ELECSYS AMHMalfunction
1823260-2025-00326 · Received Feb 4, 2025 · Event dated Jan 11, 2025
Device type: Anti-Müllerian Hormone Test System (PQO)
Device problem as coded: High Test Results; Material Integrity Problem; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ELECSYS AMHMalfunction
1823260-2022-03691 · Received Nov 20, 2022 · Event dated Oct 21, 2022
Device type: Anti-Müllerian Hormone Test System (PQO)
Device problem as coded: Low Test Results; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ELECSYS AMHMalfunction
1823260-2022-03255 · Received Oct 19, 2022 · Event dated Sep 8, 2022
Device type: Anti-Müllerian Hormone Test System (PQO)
Device problem as coded: Low Test Results; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys AMH"[tiab]. The summary above synthesizes these.
- Elecsys® AMH assay: Determination of Anti-Müllerian hormone levels and evaluation of the relationship between superovulation response in Holstein dairy cows.
Koca D, Aktar A, Turgut AO, et al. · Vet Med Sci · 2024Research Support, Non-U.S. Gov't
- Elecsys(®) AMH Assay: A Review in Anti-Müllerian Hormone Quantification and Assessment of Ovarian Reserve.
Deeks ED · Mol Diagn Ther · 2015Review
- Analytical Evaluation of Lumipulse Anti-Mullerian Hormone Assay.
Fraissinet F, Gesland A, Guillerme J, et al. · Clin Lab · 2021
- Antimüllerian hormone to determine polycystic ovarian morphology.
Dietz de Loos A, Hund M, Buck K, et al. · Fertil Steril · 2021Multicenter Study, Validation Study
- Diagnostic value of anti-Müllerian hormone combined with androgen-levels in Chinese patients with polycystic ovary syndrome.
Jiang L, Ruan X, Li Y, et al. · Gynecol Endocrinol · 2023
- Establishment of a homogeneous immunoassay-light-initiated chemiluminescence assay for detecting anti-Müllerian hormone in human serum.
Yu Y, She T, Huang L, et al. · J Immunol Methods · 2021Research Support, Non-U.S. Gov't
- New AMH assay allows rapid point of care measurements of ovarian reserve.
Pastuszek E, Lukaszuk A, Kunicki M, et al. · Gynecol Endocrinol · 2017Comparative Study
- Prospective validation of anti-Müllerian hormone cutoff to determine polycystic ovarian morphology: HARMONIA study.
Piltonen TT, Kinnunen J, Komsi E, et al. · Fertil Steril · 2025Observational Study, Validation Study
- Evaluating the PCOS risk algorithm (PriskA): a pilot study.
van der Ham K, Sillman J, Hund M, et al. · J Ovarian Res · 2026
- Inter-cycle variability of anti-Müllerian hormone: implications for predicting controlled ovarian stimulation cycle outcomes.
Şükür YE, Aslan B, Kaplan NB, et al. · J Ovarian Res · 2024
- Economic impact of the Elecsys anti-Müllerian hormone Plus immunoassay for anti-Müllerian hormone testing as part of polycystic ovary syndrome assessment in the United Kingdom.
Garay OU, Olziersky AM, Laven J, et al. · PLoS One · 2025Research Support, Non-U.S. Gov't
- Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays.
Nelson SM, Pastuszek E, Kloss G, et al. · Fertil Steril · 2015Evaluation Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PQO.
- Access AMHBeckman Coulter, Inc. · 510(k) 2023
- ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2023
- Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5Roche Diagnostics · De Novo 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.